All In Biotech

Drug Trial Radar · NCT07268638

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Praliciguat in Patients With Biopsy-Confirmed Focal Segmental Glomerulosclerosis

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 3, 2025

Primary completion

Jun 2027

Study completion Jan 2028

Sponsor

Lead sponsor
Akebia TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of praliciguat in adults with biopsy-confirmed focal segmental glomerulosclerosis (FSGS). Participants will be randomized 1:1 to receive praliciguat or placebo for initial 24 week treatment period. Following this double-blind period, all participants will receive praliciguat in an open-label period for an additional 24 weeks. Participants responding to treatment will be offered the opportunity to participate in the long-term safety extension study.

Conditions

  • Focal Segmental Glomerulosclerosis

Interventions

  • Praliciguat (Part A)Drug

    Oral Tablet

  • Placebo (Part A)Other

    Oral Tablet

  • Praliciguat (Part B)Drug

    Oral Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in urine protein-to-creatinine ratio (UPCR) (Part A)Time frame: Baseline (Day 1) and up to Week 24
  2. Proportion of participants with TEAEs, serious adverse events (SAEs), and treatment-emergent adverse events of special interest (AESIs). (Part A)Time frame: Time Frame: Up to Week 52

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Investigator Site #2

    Chula Vista, California · Recruiting

  • Investigator Site #28

    Garden Grove, California · Recruiting

  • Investigator Site #14

    Los Angeles, California · Recruiting

  • Investigator Site #12

    San Dimas, California · Recruiting

  • Investigator Site #13

    Arvada, Colorado · Recruiting

  • Investigator Site #17

    Boca Raton, Florida · Recruiting

  • Investigator Site #6

    Coral Springs, Florida · Recruiting

  • Investigator Site #25

    Hialeah, Florida · Recruiting

  • Investigator Site #7

    Miami, Florida · Recruiting

  • Investigator Site #8

    Orlando, Florida · Recruiting

  • Investigator Site #29

    Augusta, Georgia · Recruiting

  • Investigator Site # 1

    Lawrenceville, Georgia · Recruiting

  • Investigator Site #3

    Chicago, Illinois · Terminated

  • Investigator Site #11

    Louisville, Kentucky · Recruiting

  • Investigator Site #32

    Catonsville, Maryland · Recruiting

  • Investigator Site #24

    Worcester, Massachusetts · Recruiting

  • Investigator Site #15

    Livonia, Michigan · Recruiting

  • Investigator Site #10

    Pontiac, Michigan · Recruiting

  • Investigator Site #27

    Valhalla, New York · Recruiting

  • Investigator Site #16

    New Bern, North Carolina · Recruiting

  • Investigator Site #31

    Shelby, North Carolina · Recruiting

  • Investigator Site #20

    Cleveland, Ohio · Recruiting

  • Investigator Site #30

    Bethlehem, Pennsylvania · Recruiting

  • Investigator Site #19

    Bridgeville, Pennsylvania · Recruiting

  • Investigator Site #22

    Butler, Pennsylvania · Recruiting

  • Investigator Site #23

    Goose Creek, South Carolina · Recruiting

  • Investigator Site #4

    Chattanooga, Tennessee · Recruiting

  • Investigator Site #5

    Arlington, Texas · Recruiting

  • Investigator Site #21

    Dallas, Texas · Recruiting

  • Investigator Site #9

    Dallas, Texas · Recruiting

  • Investigator Site #18

    Houston, Texas · Recruiting

  • Investigator Site #26

    Roanoke, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.